Navigation Links
Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
Date:6/24/2009

ond phase inhibition, leading us to evaluate CTS-1027 in combination with ribavirin," said Steven J. Mento, President and CEO of Conatus. "We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate to fill an important medical need in HCV-infected patients."

Conatus Pharmaceuticals Inc. is a privately-held specialty pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease. Chronic liver disease affects millions of people worldwide and can be caused by many different conditions or "insults" to the liver including Hepatitis C and other viral infections, obesity, chronic alcohol abuse or autoimmune diseases. Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com


'/>"/>
SOURCE Conatus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
3. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
4. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
5. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
6. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
7. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
8. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
9. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
10. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
11. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)...  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... Healthcare Products®," today announced the closing of Perrigo,s previously ... 6,809,210 ordinary shares at a public offering price of ... option to purchase up to an additional 888,157 ordinary ... Inc., as representatives of the several underwriters. ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... Scientific Sessions of the ... American Diabetes Association, SAN FRANCISCO, June 7 ... LLY ), and Alkermes, Inc.,(Nasdaq: ALKS ) announced results ... a long-acting release formulation of,exenatide, to BYETTA(R) (exenatide) injection. Type 2 ...
... ADA,s Annual Scientific Sessions demonstrated the, value of beginning ... ... SAN FRANCISCO, June 7 Results from a ... Annual,Scientific Sessions reinforce the importance of promptly initiating insulin,treatment ...
Cached Medicine Technology:Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 2Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 3Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 4Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 5Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 6Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 7Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight 8Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control 2Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control 3Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control 4
(Date:11/28/2014)... Florida (PRWEB) November 28, 2014 On ... Turbana and Sendik’s will present Feeding America Eastern Wisconsin ... Sendik’s Food Market to donate a portion of proceeds ... in Sendik’s promotion, “7 Days, 7 Ways to Save” ... fall, Fyffes pineapples were two for $4 and Turbana ...
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... of Quintessa Aesthetic Center into a third location in ... N1497 Golf Road in Suite 200 and will open ... new Delafield location will offer a variety of ... filler injectables , micro laser peels, chemical peels, ...
(Date:11/28/2014)... Miami, FL (PRWEB) November 28, 2014 ... contemporary, responsive website. Practice founder Dr. Jeffrey ... site. Created using a groundbreaking WordPress platform, the ... devices. , Currently, up to 75% of ... More than ever, these people are logging on with ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 The ... healthy growth over the past five years. The ... acceptance of therapies that are either alternative to ... According to IBISWorld industry analyst David Whytcross, “industry ... population and growing private health insurance membership.” Meanwhile, ...
(Date:11/28/2014)... Colorado (PRWEB) November 28, 2014 Written and ... , Brook Forest Voices releases the “The Happiest Man ... , a compelling account of how and why Project C.U.R.E. ... Idaho by his mother Josie and the Reverend Richard W. ... by the age of 30, but realized that he wasn’t ...
Breaking Medicine News(10 mins):Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2
... Discovery may lead to treatments for the genetic disease, a ... (HealthDay News) -- By targeting one gene, scientists have been ... X syndrome, the most common inherited form of childhood retardation. ... gene for "fragile X mental retardation protein" (FMRP). It affects ...
... DIEGO, Dec. 19 AMN Healthcare Services,Inc. (NYSE: ... to make a presentation on Wednesday, January 9, 2008 ... Healthcare Conference taking,place at the Westin St. Francis in ... Executive Officer of AMN,Healthcare, and David C. Dreyer, Chief ...
... honor for organizational performance excellence, ANN ARBOR, Mich., ... Ford Health System as a 2007 Quality Leadership Award,recipient., ... honor for,organizational performance excellence in the state. It is ... who perform a comprehensive site,visit and then submit a ...
... Hospital Data, LANSING, Mich., Dec. 19 ... employers and other consumers with more,information than has ... charges,payments and quality of care at Michigan hospitals., ... a voluntary consumer,service of the Michigan Health & ...
... the,National Council on Disability,s monthly bulletin for November ... charge and at NCD,s award-winning Web,site (http://www.ncd.gov ... affecting people,with disabilities. To subscribe to the NCD ... mailing list archives,select NCD-NEWS-L, click on Join or ...
... Dec. 19 The Bush administration,and its supporters ... a,spending bill that fails to adequately fund medical ... bill approved by the House is a,real heartbreaker ... disease,and stroke and their loved ones. We,re extremely ...
Cached Medicine News:Health News:Fragile X Syndrome Corrected in Mice 2Health News:Fragile X Syndrome Corrected in Mice 3Health News:AMN Healthcare Services to Present at the 26th Annual JPMorgan Healthcare Conference 2Health News:Michigan Quality Council (MQC) Names Henry Ford Health System 2007 State Quality Award Recipient 2Health News:New Web Site Opens Window on Charges, Payments, Quality of Care at Michigan Hospitals 2Health News:New Web Site Opens Window on Charges, Payments, Quality of Care at Michigan Hospitals 3Health News:National Council on Disability Monthly Bulletin for November 2007 2Health News:National Council on Disability Monthly Bulletin for November 2007 3Health News:National Council on Disability Monthly Bulletin for November 2007 4Health News:National Council on Disability Monthly Bulletin for November 2007 5Health News:Statement by American Heart Association Immediate-Past President Raymond Gibbons, M.D. on Congressional Omnibus Spending Bill 2
... Ateles is a scaleable device ... volume of platelet plasma or ... or buffy coat must be ... and techniques. Starting volume and ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: